tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports
Want to see IKT full AI Analyst Report?

Inhibikase Therapeutics (IKT) Earnings Dates, Call Summary & Reports

380 Followers

Earnings Data

Report Date
Aug 17, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.11
Last Year’s EPS
-0.11
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 6 Analysts Ratings

Earnings Call Summary

Q2 2024
Earnings Call Date:Aug 14, 2024|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.
Company Guidance
During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.
Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Progress with IkT-001Pro for PAH
The company filed the IND for IkT-001Pro targeting pulmonary arterial hypertension (PAH) and plans to initiate a Phase IIb study. The market value for PAH treatments is estimated at $7.7 billion annually.
Financial Strength
Inhibikase raised $4 million from a registered direct offering and concurrent private placement, extending their cash runway into December 2024.
Decrease in Net Loss
Net loss for Q2 2024 was $5.0 million, or $0.66 per share, compared to $5.8 million, or $0.94 per share, for Q2 2023, indicating improved financial management.

Inhibikase Therapeutics (IKT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

IKT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 17, 2026
2026 (Q2)
-0.11 / -
-0.11―――
May 12, 2026
2026 (Q1)
-0.11 / -0.10
-0.1533.33% (+0.05)――
Mar 26, 2026
2025 (Q4)
-0.10 / -0.10
0.88-111.36% (-0.98)――
Nov 14, 2025
2025 (Q3)
-0.13 / -0.13
-0.6580.00% (+0.52)――
Aug 14, 2025
2025 (Q2)
-0.08 / -0.11
-0.6683.33% (+0.55)――
May 14, 2025
2025 (Q1)
-0.10 / -0.15
-0.7379.45% (+0.58)――
Mar 27, 2025
2024 (Q4)
-0.09 / 0.88
-0.64237.50% (+1.52)――
Nov 14, 2024
2024 (Q3)
-0.48 / -0.65
-0.8624.42% (+0.21)――
Aug 14, 2024
2024 (Q2)
-0.67 / -0.66
-1.1140.54% (+0.45)―
May 16, 2024
2024 (Q1)
-0.79 / -0.73
-0.9623.96% (+0.23)―
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

IKT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
$1.92$1.90-1.04%
Mar 26, 2026
$1.63$1.68+3.07%
Nov 14, 2025
$1.53$1.52-0.65%
Aug 14, 2025
$1.71$1.75+2.34%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Inhibikase Therapeutics (IKT) report earnings?
Inhibikase Therapeutics (IKT) is schdueled to report earning on Aug 17, 2026, After Close (Confirmed).
    What is Inhibikase Therapeutics (IKT) earnings time?
    Inhibikase Therapeutics (IKT) earnings time is at Aug 17, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is IKT EPS forecast?
          IKT EPS forecast for the fiscal quarter 2026 (Q2) is -0.11.